White Papers
| How lessons from the factory can optimise capacity in PV operations | |
| LEARN MORE >> |
| Achieving capability and capacity to operate an effective PV system | |
| LEARN MORE >> |
| Blending a change management framework with a risk management approach | |
| LEARN MORE >> |
| All futures are unpredictable, but some are more unpredictable than others | |
| LEARN MORE >> |
| A call for a huge cultural and technology shift in the world of drug development | |
| LEARN MORE >> |
| How life science companies can both manage risk and manage the regulator | |
| LEARN MORE >> |
| How pharma companies can develop effective lifecycle-long safety risk management | |
| LEARN MORE >> |
| Increasingly beleaguered, pharma in general and biopharma in particular still shiver at the edge of the pool of lean operations, ... | |
| LEARN MORE >> |
| Increased regulations and worried consumers are just two of the factors driving trends in drug safety and risk management today | |
| LEARN MORE >> |
| What are the factors that compel a PVO to make a decision of such significance? | |
| LEARN MORE >> |
| Making fundamental change in a regulated manufacturing environment requires a holistic approach | |
| LEARN MORE >> |
| Just as we think we're sorted, the regulators shift the goalposts... | |
| LEARN MORE >> |
| While drug safety can be a source of competitive advantage, there is a greater mutual benefit in sharing experience and common ... | |
| LEARN MORE >> |
| Fewer potential new drugs, fewer mass market opportunities, candidate drop out, declining returns...just some of todays pressures ... | |
| LEARN MORE >> |
| Periodic safety update reports can be seen as a time consuming exercise or as a positive step towards proactive pharmacovigilance | |
| LEARN MORE >> |
| Commercial pressures are driving pharma companies to look for new, smarter ways of working | |
| LEARN MORE >> |